A Class of Embedded DG Methods for Dirichlet Boundary Control of Convection Diffusion PDEs

We investigated an hybridizable discontinuous Galerkin (HDG) method for a convection diffusion Dirichlet boundary control problem in our earlier work [SIAM J. Numer. Anal. 56 (2018) 2262-2287] and obtained an optimal convergence rate for the control under some assumptions on the desired state and the domain. In this work, we obtain the same convergence rate for the control using a class of embedded DG methods proposed by Nguyen, Peraire and Cockburn [J. Comput. Phys. vol. 302 (2015), pp. 674-692] for simulating fluid flows. Since the global system for embedded DG methods uses continuous elements, the number of degrees of freedom for the embedded DG methods are smaller than the HDG method, which uses discontinuous elements for the global system. Moreover, we introduce a new simpler numerical analysis technique to handle low regularity solutions of the boundary control problem. We present some numerical experiments to confirm our theoretical results

Interpolatory HDG Method for Parabolic Semilinear PDEs

We propose the interpolatory hybridizable discontinuous Galerkin (Interpolatory HDG) method for a class of scalar parabolic semilinear PDEs. The Interpolatory HDG method uses an interpolation procedure to efficiently and accurately approximate the nonlinear term. This procedure avoids the numerical quadrature typically required for the assembly of the global matrix at each iteration in each time step, which is a computationally costly component of the standard HDG method for nonlinear PDEs. Furthermore, the Interpolatory HDG interpolation procedure yields simple explicit expressions for the nonlinear term and Jacobian matrix, which leads to a simple unified implementation for a variety of nonlinear PDEs. For a globally-Lipschitz nonlinearity, we prove that the Interpolatory HDG method does not result in a reduction of the order of convergence. We display 2D and 3D numerical experiments to demonstrate the performance of the method

An HDG Method for Dirichlet Boundary Control of Convection Dominated Diffusion PDE

We first propose a hybridizable discontinuous Galerkin (HDG) method to approximate the solution of a \emph{convection dominated} Dirichlet boundary control problem. Dirichlet boundary control problems and convection dominated problems are each very challenging numerically due to solutions with low regularity and sharp layers, respectively. Although there are some numerical analysis works in the literature on \emph{diffusion dominated} convection diffusion Dirichlet boundary control problems, we are not aware of any existing numerical analysis works for convection dominated boundary control problems. Moreover, the existing numerical analysis techniques for convection dominated PDEs are not directly applicable for the Dirichlet boundary control problem because of the low regularity solutions. In this work, we obtain an optimal a priori error estimate for the control under some conditions on the domain and the desired state. We also present some numerical experiments to illustrate the performance of the HDG method for convection dominated Dirichlet boundary control problems

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570